These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 456557)

  • 21. Comparative carcinogenicity of N-isopropyl-alpha-(2-methylhydraziono)-p-toluamide. HCI (procarbazine hydrochloride), its degradation products, other hydrazines, and isonicotinic acid hydrazide.
    Kelly MG; O'Gara RW; Yancey ST; Gadekar K; Botkin C; Oliverio VT
    J Natl Cancer Inst; 1969 Feb; 42(2):337-44. PubMed ID: 5765465
    [No Abstract]   [Full Text] [Related]  

  • 22. Analysis of animal carcinogenicity experiments with multiple tumor types.
    Lu Y; Malani HM
    Biometrics; 1995 Mar; 51(1):73-86. PubMed ID: 7766797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aging as a confounding factor in carcinogenicity bioassays.
    von Wittenau MS; Gans DJ
    Drug Chem Toxicol; 1981; 4(4):307-10. PubMed ID: 7344908
    [No Abstract]   [Full Text] [Related]  

  • 24. Carcinogenicity of antitumor cis-platinum(II) coordination complexes in the mouse and rat.
    Leopold WR; Miller EC; Miller JA
    Cancer Res; 1979 Mar; 39(3):913-8. PubMed ID: 427778
    [No Abstract]   [Full Text] [Related]  

  • 25. Lack of carcinogenicity in mice of 4,4-'diaminobenzanilide and 4,4'-diaminoazobenzene, two intermediates used in the manufacture of azo dyes.
    Della Porta G; Dragani TA
    Cancer Lett; 1981 Dec; 14(3):329-36. PubMed ID: 7332908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Animal experimental studies on the pharmacokinetics of carteolol].
    Lang W
    Arzneimittelforschung; 1983; 33(2a):286-9. PubMed ID: 6682319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ways of reducing zeolite carcinogenicity].
    Pylev LN; Vasil'eva LA; Kapin VM; Zubkov AA; Portov OA
    Gig Sanit; 1998; (5):57-9. PubMed ID: 9816793
    [No Abstract]   [Full Text] [Related]  

  • 28. Neurotropic pharmacological influences in experimental carcinogenesis.
    Pinchouk VG; Balitsky KP
    IARC Sci Publ; 1983; (51):275-84. PubMed ID: 6668049
    [No Abstract]   [Full Text] [Related]  

  • 29. Carcinogenicity of 1,2-dimethylhydrazine dihydrochloride in mice.
    Izumi K; Otsuka H; Furuya K
    Tokushima J Exp Med; 1980 Jun; 27(1-2):5-13. PubMed ID: 7423480
    [No Abstract]   [Full Text] [Related]  

  • 30. Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new beta-adrenergic blocking agent. Pharmacokinetic studies of carteolol in man.
    Morita S; Iinuma M; Kido M; Sakuragi S; Kohri H; Nishino H
    Arzneimittelforschung; 1977; 27(12):2380-3. PubMed ID: 23800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The inotropic and chronotropic responses of isolated canine atrium to 5-(3-tert.-butylamino-2-hydroxy)propoxy-3,4-dihydrocarbostyril hydrochloride (carteolol).
    Chiba S
    Arzneimittelforschung; 1979; 29(6):895-7. PubMed ID: 582780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacodynamics of carteolol].
    Odenthal KP
    Arzneimittelforschung; 1983; 33(2a):281-5. PubMed ID: 6132609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A short term test for carcinogenicity. Mouse embryo tissue homografts in BALB/c strain mice.
    PEACOCK PM; DICK E
    Br J Cancer; 1963 Mar; 17(1):59-61. PubMed ID: 13942209
    [No Abstract]   [Full Text] [Related]  

  • 34. Investigation on the combined action of N-nitrosodiethylamine with other carcinogens.
    Griciute L
    IARC Sci Publ; 1980; (31):813-23. PubMed ID: 6785224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ortho-Toluidine and ortho-toluidine hydrochloride.
    IARC Monogr Eval Carcinog Risk Chem Hum; 1982 Apr; 27():155-75. PubMed ID: 6955262
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical results with carteolol in patients with arrhythmias].
    Strösser W
    Arzneimittelforschung; 1983; 33(2a):339-45. PubMed ID: 6682327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ED01 study: summary and conclusions.
    Gaylor DW
    J Environ Pathol Toxicol; 1980; 3(3 Spec No):179-83. PubMed ID: 7365380
    [No Abstract]   [Full Text] [Related]  

  • 38. The ED01 study: introduction, objectives, and experimental design.
    Cairns T
    J Environ Pathol Toxicol; 1980; 3(3 Spec No):1-7. PubMed ID: 7365374
    [No Abstract]   [Full Text] [Related]  

  • 39. [Anti-arrhythmic and beta-adrenoceptor blocking activities of vanilol (author's transl)].
    Pan XX; Xiao JG; Lu YZ; Liu TP
    Zhongguo Yao Li Xue Bao; 1981 Jun; 2(2):97-101. PubMed ID: 6121452
    [No Abstract]   [Full Text] [Related]  

  • 40. Transgenic mice in carcinogenicity testing.
    Griesemer R; Tennant R
    IARC Sci Publ; 1992; (116):429-36. PubMed ID: 1428092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.